The building was a clinic. The loan was on the doctor who might leave.

An associate veterinarian, six years qualified, under contract to buy the small-animal practice she had worked in for four of them. Trailing collections $1.2 million. The premises leased, not owned. Equipment appraising at roughly $180,000. Purchase price agreed at $840,000, which the seller's advisor had derived from 0.7 times collections, a rule of thumb that circulates widely in the sector and is not wrong as a starting point.

Because the premises were leased and the equipment was modest, the intangible portion of the transaction was approximately $660,000. That figure did one thing immediately: it triggered the independent business valuation requirement.

Under the current standard operating procedure, effective June 2025 with technical updates effective March 2026, a lender must obtain an independent business valuation from a qualified source where the amount being financed, less the appraised value of real estate and equipment, exceeds $250,000, or where buyer and seller are related (1). A qualified source holds one of a defined set of credentials and must be independent of the transaction.

There is a second provision that matters more than the first and is quoted less often: loan proceeds used to facilitate a change of ownership may not exceed the business valuation (1). The valuation is not advisory. It is a ceiling.

One point of persistent confusion is worth clearing, because borrowers arrive with it. An older version of the procedure capped SBA-financed goodwill at 50 percent of the loan up to $250,000. That cap is retired. The current $250,000 figure is a trigger for obtaining a valuation, not a limit on how much goodwill may be financed (1). A borrower being told otherwise is being given superseded guidance.

So on a leased-premises veterinary acquisition, essentially the whole purchase price above equipment is intangible, the valuation requirement always engages, and the credit rests on a single question: how much of that intangible transfers to the buyer.

The practice ran two examination rooms and, on paper, two producing veterinarians. The reality was less balanced. The selling owner personally generated approximately 85 percent of collections, roughly $1,020,000. The single part-time associate produced the remainder.

That concentration is what the valuation had to price, and the mechanism is more specific than a general sense of key-person risk.

Practice valuations capitalise earnings after normalising owner compensation, and normalisation means replacing the owner's clinical production at market cost. The sector convention for associate compensation runs 20 to 22 percent of production (2). So the replacement salary is not a judgment call, it is a calculation, and it scales directly with how much the owner produces.

The study modelled the subject against a comparison practice with identical trailing collections and an identical cost base, differing only in the distribution of production.

Two things are happening at once, and both push in the same direction. The higher replacement salary reduces normalised earnings. And the concentration itself reduces the multiple, because multi-doctor practices trade materially above solo owner-reliant ones, with practices where the owner produces more than about 70 percent sitting at the bottom of the range (3).

The result is a defensible value near $420,000 against an agreed price of $840,000, on trailing collections that are identical to a practice worth roughly $1.43 million. Nothing about the practice's revenue was misstated. Everything about who produced it was decisive.

The same distinction between a headline average and this borrower's achievable performance runs through the single-unit franchise acquisition where the brand's average unit volume was not the borrower's forecast, and the underlying credit question, whether the loan is really secured by the real estate or by the practice behind it, is the one worked in the owner-occupied physician practice building.

A credit officer can reasonably ask whether the departing owner's production simply transfers to the buyer, who is after all an experienced associate already known to the clients. Partly it does. But the surrounding evidence sets the boundaries of that assumption.

Replacing a veterinarian is expensive and slow. Peer-reviewed work put the median cost of replacing an associate veterinarian at approximately $104,000 (4), and a professional association survey found the average full-time veterinarian vacancy took 15.4 months to fill (5). Associate turnover runs 16 to 20 percent annually (6), and veterinary unemployment sat near 0.7 percent in 2024 (7), so the market for replacement labour is tight even if the long-run supply picture is contested. It is contested: association research concludes existing colleges are adequate through 2035 and that shortages self-correct within two to three years (8), while a large consolidator with an interest in the shortage narrative projects a shortfall of 14,000 to 24,000 companion-animal veterinarians by 2030 (9). The study cited both and relied on neither.

The contractual protection is also weaker than lenders often assume. The federal non-compete rule was vacated, with the agency voting in September 2025 to dismiss its appeals and the rule formally removed from the Code of Federal Regulations in February 2026 (10). Enforceability now turns on state law, four states void most non-competes outright, and veterinarians generally fall outside the health-practitioner carve-outs that protect physicians (11). In this transaction the practical protection was a non-solicitation covenant rather than a non-compete, which restrains the seller from taking clients but not from practising nearby.

Set against that, the sector's SBA credit performance is genuinely strong, and the study said so. Veterinary charge-offs run in the region of 0.8 to 1.0 percent on a full-book basis against an all-industry acquisition benchmark near 2.1 percent (12). One vendor reports roughly 4.1 percent using a resolved-loan denominator (13), which is not a contradiction so much as a different fraction: it divides by loans that have finished rather than by loans that were authorised. Whichever basis is used, veterinary sits among the better-performing categories in the programme. That is precisely why the valuation discipline matters. The category performs well because these deals get underwritten to transferable earnings, not despite it.

One question sat underneath the valuation and was answered before it: could the practice grow its way out of the concentration problem by adding a second full producer?

Physically, only just. The practice ran two examination rooms. Production per full-time equivalent veterinarian in the sector runs roughly $530,000 to $575,000 (13), and throughput convention is 25 to 30 transactions per doctor per day against an average client transaction above $150 (14). Two rooms will support two producing veterinarians only if scheduling, technician support, and the appointment book are all running efficiently, and the accepted staffing ratio is four to five support staff per veterinarian (15). The practice was running below that ratio, which is a common reason a second doctor underperforms after arriving: the constraint is rarely the doctor, it is the team around the doctor.

The cost structure set the second boundary. Drugs, medical supplies, and laboratory run 20 to 25 percent of revenue in a well-managed small-animal practice, non-doctor staff compensation 18 to 25 percent, and doctor compensation the 20 to 22 percent of production already discussed (16). Net income for a solo owner-operator practice sits around 10 to 15 percent, rising to 15 to 20 percent for well-managed multi-doctor practices, a threshold that is reliably reached only above roughly $1 million of revenue (17). The subject was above that revenue line and below that margin line, which is itself diagnostic: the gap was going into the owner's own compensation, which is exactly the item the normalisation strips out.

So the growth case existed but it was slow and it was capital-first. Hire an associate, staff the support ratio properly, fill the second room, and the practice migrates toward the multi-doctor cost structure and the multi-doctor multiple over perhaps three years. That is a credible business plan. It is not a basis on which to size a loan today, because the lender would be advancing against earnings the practice has not yet produced with a doctor it has not yet hired in a labour market where the average vacancy takes fifteen months to fill.

One further finding sat underneath the valuation and constrained any growth assumption.

Patient visits fell 3.1 percent in 2025 across a transactional dataset covering roughly 6,500 practices, a fourth consecutive annual decline, while revenue rose about 2.5 percent on price rather than volume (14)(15). New clients account for around 8 percent of practice revenue and the canine backfill is thinning (16). A projection built on visit growth was not available. A projection built on continued price increases had to confront the same price sensitivity that is suppressing visits.

The study therefore held volume flat, grew revenue at a rate below recent price growth, and tested the coverage against a flat-revenue case. That is a conservative posture and it was the defensible one.

The practice was a good practice. The buyer was the right buyer, arguably the only buyer who could hold the client base together. And the price was set against a revenue figure that would not survive the owner's departure at the compensation the buyer would have to pay to replace her.

The specific conclusion was that approximately $420,000 of the intangible value was transferable and the balance was personal to the seller. That distinction is testable rather than rhetorical, and the study tested it three ways: the share of revenue from clients seen by the owner against those seen by the associate, the composition and durability of referral sources, and client retention history through prior associate departures.

The obvious commercial fix is unavailable here, and that is the part of this file worth knowing.

An earnout is prohibited, because the purchase price must be fixed and determinable at closing and loan proceeds cannot exceed the valuation (17). A seller note whose principal flexes with post-closing retention is not permitted for the same reason: the principal must be fixed. A holdback or escrow used to defer part of the price is treated as prohibited deferred consideration.

Nor is a phased buy-in available in the form buyers usually propose. Partial changes of ownership are permitted, but only as a purchase of stock or membership units rather than assets, with at least one original owner remaining, and any seller retaining equity must give a full personal guaranty. Pre-arranged multi-step buyouts are not permitted, and all ownership must transfer at a single closing (18).

What the transaction did instead, within the rules:

The price came down to the valuation, which is not a negotiating position but a programme requirement, and the seller accepted it once the normalisation arithmetic was in front of both parties in one document.

A seller note took part of the consideration on full standby for the life of the loan, which is the only form in which a seller note counts toward the equity injection (19).

The seller stayed for a transition under a consulting agreement, capped at twelve months, which is the maximum permitted after a complete change of ownership; she could not remain an officer, director, shareholder or employee (20).

Key-person life and disability cover on the buyer was assigned to the lender, which the procedure requires where the business depends on one owner's active participation and a collateral shortfall exists (21).

And the non-solicitation covenant was extended and separately consideration-supported, since it was doing the work the non-compete could not.

On a leased-premises professional practice, there is almost no real estate in the collateral and the equipment is a rounding error. The loan is secured by earnings, and the earnings are produced by named people. The only question that matters is how much of the production survives the closing, and it has an arithmetic answer rather than a qualitative one.

The reviewable version is short. State each producer's share of collections. Compute the replacement cost of the departing producer's share at the market compensation convention. Recompute earnings after that replacement. Apply the multiple appropriate to the resulting concentration rather than to the revenue. Then confirm that the price sits at or below the valuation, because loan proceeds cannot exceed it.

Where the answer is uncomfortable, the honest response is to resize rather than to reach for a structure the programme does not permit. Most of these deals resize. The ones that fail tend to be the ones where somebody tried to bridge the gap with an earnout.

SBA standard operating procedure 50 10 8, effective June 2025 with technical updates effective March 2026: independent business valuation trigger, qualified source credentials, and the provision that loan proceeds may not exceed the business valuation.

Sector convention on associate veterinarian compensation as a percentage of production, veterinary practice management literature.

Veterinary practice valuation multiples by practice size and producer concentration, transaction advisory and brokerage sources. Commercial parties with an interest in headline values, cited as ranges.

Peer-reviewed analysis of the economic cost of veterinarian turnover, published in a veterinary science journal, 2022.

Professional association staffing and retention survey, average time to fill a full-time veterinarian vacancy.

Associate veterinarian turnover rates, professional association data.

Veterinary unemployment rate, association economic reporting, 2024.

Association and journal analysis concluding existing veterinary colleges are adequate to meet companion-animal demand through 2035.

Consolidator-published projection of a companion-animal veterinarian shortfall by 2030. An interested commercial party.

Federal Trade Commission vote to dismiss appeals in the non-compete rule litigation, September 2025, and removal of the rule from the Code of Federal Regulations, February 2026.

State law treatment of non-competes, including the four states voiding most such covenants and the general exclusion of veterinarians from health-practitioner carve-outs.

SBA loan performance data for the veterinary industry code on a full-book basis, and the all-industry acquisition benchmark, vendor analysis of agency data through September 2025.

Production per full-time equivalent veterinarian, professional association financial and productivity benchmarking data.

Transactions per doctor per day and average client transaction benchmarks, veterinary practice management sources.

Veterinarian to support staff ratio guidance, professional association.

Cost of goods, laboratory, and staff compensation as percentages of revenue, veterinary practice management consultancy benchmarks.

Net income and earnings margin benchmarks by practice size, veterinary practice advisory sources.

Alternative veterinary charge-off figure computed on a resolved-loan denominator, vendor analysis.

Transactional visit data across approximately 6,500 practices, 2025.

Association economic reporting on revenue growth driven by price rather than volume, presented January 2026.

Association chief economist on the share of practice revenue derived from new clients.

Prohibition on earnouts and the fixed and determinable price requirement, standard operating procedure 50 10 8 as analysed in lender and legal commentary.

Partial change of ownership rules under standard operating procedure 50 10 8, including the stock purchase requirement, the retained-owner condition, and the prohibition on pre-arranged phased buyouts.

Equity injection and full standby seller note treatment under standard operating procedure 50 10 8.

Restrictions on the seller's post-closing role and the twelve-month consulting cap.

Life insurance requirement where the business depends on one owner's active participation and a collateral shortfall exists.

Method note. Programme rules are drawn from the standard operating procedure and are stated as rules. Valuation multiples, compensation conventions, and operating benchmarks come from commercial and brokerage sources and are stated as ranges. The worked comparison applies those ranges to two constructed production profiles and demonstrates the mechanism rather than valuing any practice. Where two sources disagree, as on the veterinary charge-off rate and the long-run labour supply outlook, both are stated with their basis rather than reconciled.